{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-056658","form_type":"8-K","ticker":"ARMP","cik":"0000921114","company_name":"Armata Pharmaceuticals, Inc.","filed_at":"2026-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.937007+00:00","generated_at":"2026-05-14T22:24:15.636654+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Armata receives FDA Fast Track for AP-SA02 phage therapy for S. aureus bacteremia","bullets":["Fast Track designation enables rolling BLA review and potential Accelerated Approval and Priority Review.","Phase 3 superiority study anticipated to begin in H2 2026.","AP-SA02 targets complicated bacteremia from MSSA and MRSA.","FDA designation underscores unmet need in severe, often deadly S. aureus infections."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-056658","json":"https://secwatch.observer/filing/0001104659-26-056658.json","markdown":"https://secwatch.observer/filing/0001104659-26-056658.md","text":"https://secwatch.observer/filing/0001104659-26-056658.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921114/000110465926056658/0001104659-26-056658-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921114/000110465926056658/tm2613773d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T22:24:15.636654+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}